Kairos Pharma, Ltd.

AMEX: KAPA · Healthcare · Biotechnology

PublicHQ Los Angeles, CA · Los AngelesCIK 0001962011Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 52DQ —GM —SS 17

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ workforce scale, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$5.4M

Employees

Market cap

$7.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$5.4M-$5.4M2025

Operating income-$5.6M-$5.6M2025

Total assets$6.5M$6.5M2025

Liabilities$992.0k$992.0k2024

Equity$6.3M$6.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Kairos Pharma, Ltd. earned -$5.4M in FY2025 net income.

Peers · Healthcare

SpotLite360 IOT Solutions, Inc.——Polarean Imaging plc——OSR Holdings, Inc.33D Intensity Therapeutics, Inc.——

Neighbors

Los Angeles →

The Walt Disney Company$94.4B71B Rocket Lab USA, Inc.$601.8M50D Public Storage$4.8B79B+Live Nation Entertainment, Inc.$25.2B76B+Ares Management Corporation$5.6B67B Edison International$19.3B81B+

Key facts

CEOJohn S. Yu

SectorHealthcare

IndustryBiotechnology

HeadquartersLos Angeles, CA

ExchangeAMEX: KAPA

Employees1

IPO date2024-09-16

Latest filings

8-K2026-06-30 8-K2026-06-04 DEF 14A2026-05-22 8-K2026-05-18 10-Q2026-05-13 10-K2026-03-31 8-K2026-03-02 8-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.